Analyst Ratings For Intra-Cellular Therapies
Portfolio Pulse from Benzinga Insights
Intra-Cellular Therapies (NASDAQ:ITCI) has been the subject of diverse analyst ratings over the last three months, with a total of 18 analysts offering opinions ranging from bullish to bearish. The average 12-month price target for ITCI has been raised to $91.94, marking an 11.44% increase from the previous average of $82.50. Analysts from firms including Needham, Cantor Fitzgerald, Canaccord Genuity, Mizuho, Goldman Sachs, B of A Securities, TD Cowen, Baird, and RBC Capital have updated their ratings and price targets, reflecting a generally positive outlook on the company's performance. Intra-Cellular Therapies, a biopharmaceutical company focusing on central nervous system diseases, has shown a notable revenue growth rate of 50.41% over the past three months, despite challenges in net margin, ROE, and ROA.

May 08, 2024 | 8:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Intra-Cellular Therapies has received updated analyst ratings and price targets, with a notable increase in the average 12-month price target to $91.94. The company has demonstrated significant revenue growth, although it faces challenges in profitability and asset utilization.
The positive revisions in analyst ratings and price targets, combined with significant revenue growth, suggest a bullish outlook for ITCI in the short term. However, investors should be cautious of the company's below-average net margin, ROE, and ROA, which may pose challenges to profitability and efficient capital utilization.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100